| Market Cap | 18.07M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -252.85M | Forward P/E | -15.47 | EPS next Y | - | 50D Avg Chg | 12.00% |
| Sales | 117.63M | PEG | - | EPS past 5Y | 16.45% | 200D Avg Chg | 7.00% |
| Dividend | N/A | Price/Book | 0.23 | EPS next 5Y | 46.00% | 52W High Chg | -40.00% |
| Recommedations | 2.00 | Quick Ratio | 0.21 | Shares Outstanding | 1.24M | 52W Low Chg | 186.00% |
| Insider Own | 0.69% | ROA | -5.77% | Shares Float | 1.22M | Beta | 1.46 |
| Inst Own | 13.22% | ROE | - | Shares Shorted/Prior | 8.10K/11.08K | Price | 14.85 |
| Gross Margin | 82.63% | Profit Margin | -214.95% | Avg. Volume | 57,637 | Target Price | - |
| Oper. Margin | 3.90% | Earnings Date | May 2 | Volume | 3,453 | Change | 1.30% |
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.